

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Li et al.

Application Serial No: 09/348,815

Art Unit: 1635

Filed: July 8, 1999

Examiner: Zara, J.

For: Connective Tissue Growth Factor-2

Docket No: PF126P1D1

Cap 1635
RECEIVED

OCT 25 2000

TECH CENTER 1600/2300

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the References AA-AU listed on the attached revised Form PTO/SB/08.

This application is a divisional of U.S. Application Serial No. 08/459,101, filed 2 June 1995, now U.S. Patent No. 5,945,300, priority to which is claimed under 35 U.S.C. § 120. Thus, in accordance with 37 C.F.R. § 1.98(d), Applicants respectfully direct the Examiner to the file of Application No. 08/459,101 for copies of References AA, AC, AG-AN, and AP-AT. A copy of References AB, AD-AF, AO and AU is enclosed.

In addition, Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to:

- (a) SEQ ID NOS: 30 and 143, in copending U.S. Patent Application Serial No. 08/196,363;
- (b) SEQ ID NOS: 1412, 46, 646, 662 and 680 in copending U.S. Patent Application Serial No. 08/196,482;
- (c) SEQ ID NO: 1855 in copending U.S. Patent Application Serial No. 08/985,366;
- (d) SEQ ID NO: 515 in copending U.S. Patent Application Serial No. 08/103,743;
- (e) SEQ ID NO: 15037 in copending U.S. Patent Application Serial No. 08/401,791;
- (f) SEQ ID NO: 73 in copending U.S. Patent Application Serial No. 08/345,704;
- and
- (g) SEQ ID NO: 10 in copending U.S. Patent Application Serial No. 08/401,881.

Applicants respectfully request that the Examiner review the materials and information identified above and that they be made of record in the file history of the application.

Identification of the materials and information identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted

Date: October 17, 2000


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosures
/rc